UPS today announced that its board of directors has appointed Angela Hwang to the board, effective immediately.
Hwang, age 54, is a member of Pfizer’s Executive Team and is Group President of the Pfizer Biopharmaceuticals Group, which comprises approximately 80% of Pfizer’s revenues. In this role, she leads more than 26,000 global colleagues and has responsibility for bringing over 600 innovative medicines and products to patients around the world.
“The UPS Board engaged in a thorough search and evaluation to find the right candidate for this role,” said UPS Executive Chairman of the Board David Abney. “Angela’s expertise in the healthcare sector will bring added talent to our Board as we oversee the company’s strategic growth efforts in this area.”
Hwang oversees seven commercial business units, which in 2019 generated nearly $40 billion in revenues, and impacted the lives of over 434 million patients across 125 countries. Together, these businesses strive to deliver transformational medicines that address major global health priorities in cancer, rare disease, inflammation & immunology, primary care, infectious diseases, and preventative care with vaccines.
“Angela is an outstanding, proven leader who brings added healthcare and global management experience to our Board,” said UPS Chief Executive Officer Carol Tomé. “We couldn’t be more thrilled to welcome Angela to the UPS Board of Directors during this time when UPS continues to expand its leadership in the healthcare logistics space, launching new healthcare services for UPS customers.”
